Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7769047 | 1.00 | ALDH1A1 (0.35) | ALDH1A1PTGS1 | |
| SCHEMBL15448059 | 1.00 | ALDH1A1 (0.35) | ALDH1A1PTGS1 | |
| SCHEMBL7772981 | 0.90 | — | — | |
| SCHEMBL5599751 | 0.90 | — | — | |
| SCHEMBL12811117 | 0.90 | — | — | |
| SCHEMBL11797693 | 0.87 | — | — | |
| SCHEMBL11797697 | 0.87 | — | — | |
| SCHEMBL11579062 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11579059 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL5953057 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5312969-A | Linear dicarbonylation of difunctionalized butenes | RHONE-POULENC CHIMIE (FR) | 1994-05-17 | — | — | US | claimed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-0801128-A1 | Fuel additive | NIPPON OIL CO. LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
| EP-0612720-B1 | Process for producing 1,4-dicyano-2-butene | SUMITOMO CHEMICAL CO (JP) | 1997-01-08 | — | — | EP | disclosed |
| EP-0723985-A1 | Fuel additive | NIPPON OIL CO. LTD. (JP) | 1996-07-31 | — | — | EP | disclosed |
| EP-0612720-A1 | Process for producing 1,4-dicyano-2-butene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-08-31 | — | — | EP | disclosed |
| US-5312969-A | Linear dicarbonylation of difunctionalized butenes | RHONE-POULENC CHIMIE (FR) | 1994-05-17 | — | — | US | disclosed |
| US-5198573-A | Reaction of carbon monoxide with dialkoxy-3-butene in the presence of palladium catalysts | RHONE-POULENC CHIMIE (FR) | 1993-03-30 | — | — | US | disclosed |
| US-4857657-A | Preparation of hexenedioic acid diesters | RHONE-POULENC CHIMIE (FR) | 1989-08-15 | — | — | US | disclosed |
| US-4633015-A | CATALYTIC CARBONYLATION IN APROTIC SOLVENT, HYDROGENATION AND HYDROLYSIS | MONSANTO COMPANY (US) | 1986-12-30 | — | — | US | disclosed |
| US-4611082-A | Production of hex-3-enedioate esters from 1,4 dialkoxy butenes | MONSANTO COMPANY (US) | 1986-09-09 | — | — | US | disclosed |
| US-4168379-A | Pyridin-3-ols | BASF AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885PTGS1 1285/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885PTGS1 1285/4885 |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885PTGS1 1285/4885 |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885PTGS1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.